Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P40818

UPID:
UBP8_HUMAN

ALTERNATIVE NAMES:
Deubiquitinating enzyme 8; Ubiquitin isopeptidase Y; Ubiquitin thioesterase 8; Ubiquitin-specific-processing protease 8

ALTERNATIVE UPACC:
P40818; B4DKA8; Q2TB31; Q7Z3U2; Q86VA0; Q8IWI7

BACKGROUND:
Ubiquitin carboxyl-terminal hydrolase 8, known for its roles in deubiquitinating proteins like EPS15 and BACE1, is crucial for regulating protein degradation, cell cycle progression, and signal transduction pathways. Its ability to modulate ubiquitin dynamics underscores its importance in cellular regulation and disease mechanisms.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in the pathogenesis of Pituitary adenoma 4, ACTH-secreting, and its systemic effects such as Cushing syndrome, targeting Ubiquitin carboxyl-terminal hydrolase 8 offers a promising avenue for developing novel treatments for these conditions, emphasizing the protein's therapeutic potential.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.